Eli Lilly and Boehringer Ingelheim have found in their current randomized, double-blinded EMPEROR-Reduced Phase III trials that new exploratory sub-data showed Jardiance (empagliflozin) may help reduce the risk of heart and kidney conditions in adults with heart failure with reduced ejection fraction.
Jardiance (empagliflozin) is often used for diabetes type 2 along with diet and exercise to lower blood sugar in adults and reduces the risk of cardiovascular death in adults with the condition. The trial is analyzing the effects of once-daily Jardiance versus placebo in heart failure patients with preserved or reduced ejection fraction. The over 20730 participants are a mix of diabetes patients and no diabetes patients.
The goal of the trial was to analyze the duration to the first event of adjudicated heart failure death or adjudicated hospitalization for heart failure. The clinical trial data suggests that people who are using Jardiance have a reduced relative risk for the composite primary endpoint of death or hospitalization for heart failure by 25%. First and recurrent hospitalization for heart failure showed a reduction of 30%.
The study also showed that the drug could be beneficial for eGFR, which is a measure of kidney function in heart failure patients with and without diabetes, and can also reduce the relative risk of composite kidney endpoint, including late-stage kidney diseases and loss of kidney function, by 50%.
These findings could mean the next breakthrough in cardiovascular research and improve the quality of millions of people living with those conditions.
Partner with accredited companies
Since 2015, our team has been hard at work raising awareness of clinical trials across the globe. A Forbes ‘30 Under 30’ company and a graduate of the renowned Techstar program in New York, Citruslabs is at the forefront of patient recruitment and retention technologies. With over 3 million patients now recorded on our databases, our patient recruitment dashboard is fast becoming the most efficient method of trial recruitment.
Now a #1 health app in 17 countries, our Mindmate app is helping to revolutionize the way we think about healthcare. Mindmate “[takes] senior care into the digital age” (Forbes, 2018) by providing people with the cognitive decline the essential tools to help them rebuild and maintain strong mental health. Trusted by millions of users, our health community continues to grow as the content available expands to the needs of individuals today.
With more than 200 research sites now using the Citrus platform to screen thousands of patients every month, researchers are now well on their way to finding new treatments for hundreds of different health conditions - something that just would not be possible without a technological solution. Make sure that your clinical trial is in the lucky 12% and turn that luck into guaranteed results with Citrus.
Still a little unsure? Check out what our customers have to say about us here.
Comments